FOR AUTHORS
IMI - Therapy
All Items
-
36 | Neoadjuvant strategy for locally advanced conjunctival melanoma: a single-center approach to eye preservation F. Rifaldi1|2, M. Angi3, L. Giuseppe1, F. Lanza3, A. Spagnoletti1, J. Sergenti3, A. Indini1, E. Mastrogiuseppe3, M. Del Vecchio1, L. Di Guardo1 | 1Melanoma Medical Oncology Unit, Department of Medical Oncology ed Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 2Fondazione IRCCS Policlinico San Matteo, Pavia; 3Ocular Oncology Service, Department of Surgical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
360 -
35 | Real-world outcomes of targeted therapy in stage IV melanoma after relapse on adjuvant dabrafenib and trametinib: insights from a single-center cohort Rossella Villani, Chiara Bungaro, Anna Cecere, Ileana De Roma, Sabino Strippoli, Michele Guida | Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
327 -
34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup Francesco Spagnolo1|2, Bruna Dalmasso3, Maria Chiara Scaini4, Laura Cendron5, Monica Rodolfo6, Ilaria Mattavelli7, Elena Tamborini8, Francesca Collina9, Gerardo Ferrara, Gabriele Madonna10, Carlo Cota11, Elisa Melucci12, Stefania Tommasi13, Martina Ubaldi14, Roberta Depenni15, Andrea Carugno16, Riccardo Marconcini17, Laura Orgiano18, Maurizio Lombardo19, Simona Sola20, Cristina Pellegrini21, Francesca Castiglione22, Matteo Gasparotto5|23, Alireza Jorkesh5, Stefania Pellegrini4, Edoardo Raposio1, Andrea Boutros2, Enrica Teresa Tanda2, Michele Guida25, Pietro Quaglino26, Giuseppe Palmieri27, Daniela Massi22, Paolo Antonio Ascierto10, Mario Mandalà*28, Chiara Menin*4, Paola Ghiorzo*24, Lorenza Pastorino*24, for the Italian Melanoma Intergroup29 | 1Department of Surgical Sciences and Integrated Diagnostics, DISC, Plastic Surgery Division, University of Genoa; 2IRCCS Ospedale Policlinico San Martino, Genova; 3IRCCS Ospedale Policlinico San Martino, Cancer Genetics, Genoa; 4Immunology and Molecular Oncology Unit, Veneto Institute of Oncology - IOV IRCCS, Padua; 5Department of Biology, University of Padua, Padua; 6Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 7Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 8Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 9Pathology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli; 10Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; 11Dermatopathology Unit, San Gallicano Dermatological Institute IRCCS, Rome; 12Pathology Unit, IRCCS Regina Elena, National Cancer Institute, Rome; 13Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; 14Unit of Medical Oncology, University of Perugia; 15Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena; 16Department of Medicine and Surgery, University of Insubria, Varese; 17Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa; 18Department of Medical Oncology, University of Cagliari, Cagliari; 19Division of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese; 20Surgical Pathology, Galliera Hospital, Genoa; 21Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila; 22Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy and Section of Pathology, Department of Health Sciences, University of Florence, Italy; 23Department of Translational Brain Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 24Department of Internal Medicine and Medical Specialties, University of Genoa; 25Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari; 26Dermatology Clinic, Department of Medical Sciences, University of Turin; 27Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, Sassari; 28University of Perugia, Medical Oncology Unit, Santa Maria Misericordia Hospital, Perugia; 29Italian Melanoma Intergroup, IMI, Italy. *These authors equally contributed to this work.
307 -
33 | A single center, real world experience with hedgehog pathway inhibitors in advanced basal cell carcinoma Giulia Gibilisco1, Ramiz Anwar Rana1, Vincenzo D’Alonzo1, Maura Colucci1|2, Monica Valente2, Elisa Cinotti3, Giovanni Rubino4, Valentina Croce1, Eleonora Carbonari1, Matteo Ravara1, Tommaso Sani1, Maria Lo Fiego1, Alessia Covre1, Serena Cutarella1, Roberto Cuomo5, Luca Grimaldi5, Pietro Rubegni3, Michele Maio1|2, Anna Maria Di Giacomo1|2 | 1University of Siena; 2Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena; 3Dermatology Unit, Department of Medicine, Surgery and Neuroscience, University Hospital of Siena; 4Radiotherapy Unit, Department of Oncology, University Hospital of Siena; 5Plastic Surgery Unit, Department of Medicine, Surgery and Neuroscience, University Hospital of Siena; 6NIBIT Foundation Onlus, Genoa, Italy.
299 -
32 | Tebentafusp in metastatic uveal melanoma: 3 years of real world data and insights from liquid biopsy Luisa Piccin1, Maria Chiara Scaini2, Valentina Salizzato1, Cristina Catoni2, Elisabetta Di Liso1, Alice Menichetti1, Chiara Cacco1|4, Chiara Gottardi1|4, Francesca Di Sarra3, Marina Coppola3, Valentina Guarneri1|4, Jacopo Pigozzo1 | 1Medical Oncology 2 - Veneto Institute of Oncology IOV-IRCCS; 2Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS; 3Pharmacy Unit - Veneto Institute of Oncology IOV-IRCCS; 4Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.
248 -
31 | Effectiveness and safety of adjuvant combo-targeted and immunotherapy in melanoma patients Valentina Salizzato1, Luisa Piccin1, Alessio Fabozzi2, Paolo Del Fiore3, Francesco Cavallin4, Chiara Cacco1|5, Simone Mocellin3|5, Marcodomenico Mazza3, Valentina Guarneri1|5, Jacopo Pigozzo1 | 1Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova; 2Medical Oncology 3, Veneto Institute of Oncology IOV-IRCCS, Padova; 3Soft-Tissue, Peritoneum and Melanoma Surgical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padova; 4Independent Statistician, Solagna; 5Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy.
249 -
30 | Sonidegib for nevoid basal cell carcinoma (Gorlin) syndrome and EADO stage IIb sporadic basal cell carcinomas: a phase II study (SIBLINGS trial) Sara Farinatti1|2, Giuseppe Agenziano3, Emi Dika4|5, Emanuela Passoni6, Ketty Peris7, Pietro Quaglino8, Paola Queirolo9, Massimiliano Scalvenzi10, Iris Zalaudek11, Luigi Lorini11, Cristina Gurizzan1, Monica Variolo1|2, Paolo Bossi*1|2, Carlo Resteghini*1|2 | 1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano; 2Department of Biomedical Sciences, Humanitas University, Rozzano MI; 3Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; 4Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; 5Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna; 6Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 7Institute of Dermatology, Catholic University of the Sacred Heart, Rome; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; 8Dermatologic Clinic, University of Turin Medical School, Turin; 9Medical Oncology Unit; 10Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples; 11Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste, Italy. *Contributed equally.
323 -
29 | The extracellular vesicle potential for the early detection of resistance to immunotherapy in melanoma patients Cristina Catoni1, Cristina Poggiana1, Alessandro Francesco Piazza1, Jacopo Pigozzo2, Luisa Piccin2, Chiara Menin1, Stefania Pellegrini1, Valentina Salizzato2, Paolo Del Fiore4, Simone Mocellin3|4, Vanna Chiarion-Sileni2, Valentina Guarneri2|3, Antonio Rosato1|3, Maria Chiara Scaini1 | 1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 2Medical Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padua; 3Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
268 -
28 | Efficacy and toxicity outcomes with doublet immunotherapy in metastatic melanoma: the real-world REALIPINIVO study Miriam Forte1, Francesco Caraglia1, Silvana Cozzolino1, Antonino Colloca1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Francesca Sparano5, Maria Chiara Sergi3, Teresa Del Giudice4, Immacolata Paciolla6, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi6, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples; 2Department of Clinical Medicine and Surgery, Federico Il University, Naples; 3Unità Operativa Complessa di Oncologia Medica, Ospedale "Mons. A.R. Dimiccoli", Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Napoli; 6Medical Oncology Unit AORN "San Pio", Benevento, Italy.
308 -
27 | Real-world data for malignant melanoma stage II adjuvant therapy Silvana Cozzolino1, Antonino Colloca1, Miriam Forte1, Francesco Caraglia1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Maria Chiara Sergi3, Teresa Del Giudice4, Francesca Sparano5, Immacolata Paciolla6, Mariangela Pasqualoni7, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi1, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples; 2Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy; 3Division of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples; 6Medical Oncology Unit, AORN "San Pio", Benevento, Italy; 7Medical Oncology Unit, ASL Taranto, Italy.
322 -
26 | Tumor size may predict early response to sonidegib in locally-advanced basal cell carcinoma: clinical and histopathological correlates from a monocentric case series Gabriella Perillo1, Giovanni Cecchi1, Biancamaria Zuccaro1, Federica Fazzari1, Vincenzo De Giorgi1|2 | 1Section of Dermatology, Department of Health Sciences, University of Florence; 2Cancer Research "Attilia Pofferi" Foundation, Pistoia, Italy.
264 -
25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial Monica Variolo1|2, Carlo Resteghini1|2, Sara Farinatti1|2, Andrea Alberti3, Valeria Tovazzi3, Paola Queirolo4, Maristella Saponara4, Giuseppe Argenziano5, Riccardo Marconcini6, Ketty Peris7, Paola Savoia8, Maria Chiara Tronconi1, Iris Zalaudek9, Paolo Ascierto10, Francesco Spagnolo11, Luigi Lorini1, Cristina Gurizzan1, Paolo Bossi1|2 | 1Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, Rozzano MI; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; 3Medical Oncology Unit, ASST Spedali Civili, Brescia; 4Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan; 5Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; 6Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; 7Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; 8Department of Health Sciences, University of Eastern Piedmont, Novara; 9Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste; 10Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; 11Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
295 -
24 | Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study Federico Venturi1|2|3, Biancamaria Zuccaro1, Gabriella Perillo1, Giovanni Cecchi1, Aurora Gaeta4|5, Sara Gandini4, Vincenzo De Giorgi1|6 | 1Section of Dermatology, Department of Health Sciences, University of Florence; 2Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna; 3Department of Medical and Surgical Sciences, DIMEC, Alma Mater Studiorum University of Bologna; 4Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan; 5Department of Statistics and Quantitative Methods, University of Milano-Bicocca; 6Cancer Research "Attilia Pofferi" Foundation, Pistoia, Italy.
286 -
23 | Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study Maria Chiara Sergi*1, Teresa Amaral*2, Piotr Rutkowski*3, Marie-Lena Rasch2, Naima Benannoune4, Patricio Serra5, Maria Grazia Vitale6, Diana Giannarelli7, Ana Maria Arance8, Eva Munoz Couselo9, Bart Neyns10, Iris Dirven11, Marco Tucci12, Michele Guida13, Francesco Spagnolo14, Ernesto Rossi15, Paola Queirolo16, Pietro Quaglino17, Roberta Depenni18, Joanna Placzke3, Anna Maria Di Giacomo19, Michele Del Vecchio20, Alice Indini20, Ines Pires da Silva21, Alexander M. Menzies22, Angela Hong23, Paul Lorigan5, Caroline Robert24, Georgina V. Long22, Paolo A. Ascierto6, Mario Mandalà25 | 1Unit of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Asl BT, Barletta, Italy; 2Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. 3Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 4Gustave Roussy Cancer Campus, Villejuif, France. 5The University of Manchester, Manchester, UK. 6Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy; 7Epidemiology and Biostatistics, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 8Hospital Clínic Barcelona and IDIBAPS, Barcelona, Spain; 9Department of medical oncology. Vall d"Hebron Hospital, Barcelona, Spain & Vall d’Hebron Institute of oncology, VHIO. Barcelona, Spain; 10Department of Medical Oncology, UZ Brussel, Brussels, Belgium. 11Department of medical oncology, Vrije Universiteit Brussel, VUB, Universitair Ziekenhuis Brussel, Brussels, Belgium; 12Medical Oncology Unit, University of Bari Aldo Moro, Policlinico Hospital of Bari, 70124 Bari, Italy. 13Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori "Giovanni Paolo II," Bari, Italy. 14IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy; 15Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 16IEO European Institute of Oncology, IRCCS, Milan, Italy. 17Department of Dermatology, University of Turin, Turin, Italy. 18University of Modena and Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy; 19Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. 20Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 21Melanoma Institute Australia, University of Sydney, and Blacktown Hospital, Sydney, New South Wales, Australia; 22Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; 23Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Australia; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia; 24Gustave Roussy and Paris-Saclay University, Villejuif, France; 25Unit of Medical Oncology, University of Perugia, Perugia, Italy. § on behalf of the Italian Melanoma Intergroup - IMI.
273
